

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/664,341
		Filing Date	September 16, 2003
		First Named Inventor	Zdanovsky, Alexey
		Group Art Unit	1652
		Examiner Name	Pak, Yong
Sheet 1 of 1		Attorney Docket No: 341.021US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/Y.P./		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Communication Pursuant to Article 96(2) EPC mailed 1-25-07", 4 pgs.	
/Y.P./		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Communication pursuant to Article 96(2) mailed 5-22-07", 5 pgs.	
/Y.P./		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Supplemental European Search Report mailed 8-4-2006", 7 pgs.	
/Y.P./		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1), Supplemental Partial European Search Report mailed 5-17-2006", 5 pgs.	
/Y.P./		"European Patent Application No. 03754599.3 (Atty Ref 341.023EP1), Response filed 4-20-07 to Communication mailed 1-25-07", 17 pgs.	
/Y.P./		"PCT Application No. PCT/US03/28939 (Atty Ref 341.021WO1), International Preliminary Examination Report mailed 10-12-2006", 6 pgs.	
/Y.P./		ADRAIN, C., et al., "Apoptosis-Associated Release of Smac/DIABLO From Mitochondria Requires Active Caspases and is Blocked by Bcl-2", <u>The EMBO Journal</u> , 20(23), (2001), 6627-6636	
/Y.P./		BERKERS, C. R., et al., "Activity Probe for in vivo Profiling of the Specificity of Proteasome Inhibitor Bortezomib", <u>Nature Methods</u> , 2(5), (2005), 357-362	
/Y.P./		FERNANDEZ, Y. , et al., "Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications", <u>Cancer Research</u> , 65(14), (2005), 6294-6304	
/Y.P./		KISSELEV, A. F., et al., "Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies With Protein Substrate", <u>The Journal of Biological Chemistry</u> , 281(13), (March 31, 2006), 8582-8590	
/Y.P./		KISSELEV, A. F., et al., "Monitoring Activity and Inhibition of 26S Proteasomes With Fluorogenic Peptide Substrates", <u>Methods in Enzymology</u> , Vol. 398, (2005), 364-378	
/Y.P./		LUKER, G. D., et al., "Imaging 26S Proteasome Activity and Inhibition in Living Mice", <u>Nature Medicine</u> , 9(7), (2003), 969-973	
/Y.P./		RAMSBY, M. L., "Differential Detergent Fractionation of Isolated Hepatocytes: Biochemical, Immunochemical and Two-Dimensional Gel Electrophoresis Characterization of Cytoskeletal and Noncytoskeletal Compartments", <u>Electrophoresis</u> , 15, (1994), 265-277	
/Y.P./		WILKINSON, J. C., et al., "Upstream Regulatory Role for XIAP in Receptor-Mediated Apoptosis", <u>Molecular and Cellular Biology</u> , 24(16), (2004), 7003-7014	

01/22/2008

EXAMINER	/Yong Pak/	DATE CONSIDERED
-----------------	------------	------------------------